MedTrace Logo

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

NCT05592015 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-10

No results posted yet for this study

Summary

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Conditions

  • T-Cell Large Granular Lymphocyte Leukemia

Interventions

DRUG

Ruxolitinib

Given PO

Sponsors & Collaborators

  • Jonathan Brammer

    lead OTHER

Principal Investigators

  • Jonathan Brammer, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-03
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05592015 on ClinicalTrials.gov